Cymbalta
Product Images NDC 68151-4679

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 68151-4679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Cymbalta 01)

Chemical structure diagram of the active ingredient in Cymbalta, showing a molecular arrangement with a thiophene ring, a chiral center, a benzofuran-like bicyclic structure, and an amine group as the hydrochloride salt.*

FDA Label Image

Figure 3 (Cymbalta 02)

A line graph comparing the percentage of patients improved at varying levels of percent improvement in pain from baseline. The graph includes data for Cymbalta 60 mg twice daily (BID), Cymbalta 60 mg once daily (QD), Cymbalta 20 mg once daily (QD), and placebo groups. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%.*

FDA Label Image

Figure 4 (Cymbalta 03)

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline across three groups: Cymbalta 60mg BID, Cymbalta 60mg QD, and placebo. The y-axis shows the percentage of patients improved, and the x-axis shows the percent improvement in pain from baseline, ranging from greater than 0 to 100 percent.*

FDA Label Image

Figure 5 (Cymbalta 13)

A line graph showing the percentage of patients improved against the percent improvement in pain from baseline. It compares three groups: Cymbalta 60mg twice daily, Cymbalta 60mg once daily, and placebo, plotted across increasing pain improvement percentages from greater than 0 to 100 percent.*

FDA Label Image

Figure 6 (Cymbalta 14)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. It compares four groups: Cymbalta (CYM) 120 mg once daily, CYM 60 mg once daily, CYM 20 mg once daily, and placebo, with the vertical axis representing percentage of patients improved and the horizontal axis representing percent improvement in pain.*

FDA Label Image

Figure 7 (Cymbalta 15)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It illustrates two groups: Placebo and CYM60/120 mg once daily, with the latter showing generally higher patient improvement percentages across the pain improvement spectrum.*

FDA Label Image

Figure 8 (Cymbalta 16)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between a placebo group and a group taking Cymbalta 60 mg once daily. The y-axis shows the percentage of patients improved (0-100%), and the x-axis shows percent improvement in pain. Two lines are plotted: a dotted line for placebo and a solid line with diamonds for Cymbalta 60 mg.*

FDA Label Image

Figure 9 (Cymbalta 17)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Placebo and CYM60/120 mg once daily. The graph shows two lines: one for Placebo marked with 'x' symbols and one for CYM60/120 mg once daily marked with diamond symbols, with percentage of patients improved on the vertical axis and percent improvement in pain on the horizontal axis.*

FDA Label Image

Figure 1 (Cymbalta 18)

A line graph comparing the proportion of patients with relapse over time from randomization to relapse (in days) between two treatments: placebo (dashed line) and Cymbalta (solid line). The x-axis represents time in days up to 250, and the y-axis shows the proportion of patients with relapse ranging from 0 to 1. The graph indicates differences in relapse rates over time between the two groups.*

FDA Label Image

Figure 2 (Cymbalta 19)

A line chart showing the proportion of patients with relapse over time from randomization in days, comparing treatment with Cymbalta versus placebo. The solid line represents Cymbalta, and the dashed line represents placebo, with the proportion of patients relapsing increasing more slowly for Cymbalta across the time period up to approximately 250 days.*

FDA Label Image

Label Image (Lbl681514679)

The label for Cymbalta duloxetine 30 mg delayed-release capsules displays the product name, strength, dosage form, manufacturer listed as Lilly, lot number C116094A, expiration date 07/14, and a barcode with the product NDC 68151-4679. The label also indicates Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.